<DOC>
	<DOC>NCT01423110</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis, Inclusion Body</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Antibodies, Blocking</mesh_term>
	<criteria>Males and Females aged 4080 with a confirmed diagnosis of sporadic Inclusion Body Myositis Unable to walk at least 3 meters without assistance from another person Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months patients with a history or presence of renal impairment and/or liver disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>sporadic Inclusion Body Myositis</keyword>
</DOC>